Original articleA cyclooxygenase-2 inhibitor alters Th1/Th2 cytokine balance and suppresses autoimmune myocarditis in rats
Introduction
Acute myocarditis is a serious disease in humans; patients with myocarditis may present rapidly progressive heart failure, shock, or severe arrhythmia. Although acute myocardial inflammation is an essential etiology for the progression, no effective treatment has been elucidated [1], [2], [3], [4], [5]].
Cyclooxygenase (COX)-2 is a key factor in the progression of inflammation [6], [7], [8] and several clinical diseases [9], [10]. In the cardiovascular system, COX-2 is expressed in normal and diseased hearts [11], [12], [13]. Although inflammation is an essential pathological feature of acute myocarditis, the role of COX-2 in this process remains unclear. Experimental autoimmune myocarditis (EAM) in a rat model is characterized by severe myocardial damage and multinucleated giant cell infiltration. This has been used as a disease model for human acute myocarditis [6], [7]. To clarify the role of COX-2 in acute myocarditis, we used the EAM model to evaluate the COX-2 expression in the hearts and to analyze the effect of the specific COX-2 inhibitor. We have revealed that the COX-2 is enhanced in the EAM progression and the inhibitor suppresses the development of the inflammation in this study.
Section snippets
Animals and immunization
Male Lewis rats (7-week-old; body weights 250–350 g) were purchased from Sankyo Laboratories (Tokyo, Japan). They were fed a standard diet and water and were maintained in compliance with animal welfare guidelines of the Institute of Experimental Animals, Tokyo Medical and Dental University. Purified porcine cardiac myosin (Sigma Chemical Co., St. Louis, MO, USA) was dissolved in 0.01 M phosphate-buffered saline (PBS) and emulsified with an equal volume of complete Freund's adjuvant (Difco,
The COX-2 inhibitor suppressed body weight loss, heart rate acceleration and blood pressure decline (Fig. 1)
The non-treated EAM controls (group C) showed significant body weight loss, heart rate acceleration, and decline of mean blood pressure. However, the whole phase oral administration of the COX-2 inhibitor (group P + R) suppressed body weight loss, heart rate acceleration, and decline of mean blood pressure. The priming phase (group P) and response phase (group R) administration could not suppress these values statistically. The non-immunized rats with the treatment (group NT) showed comparable
Discussion
Many clinical trials have been performed to determine whether immunosuppressive therapy improves the severity and outcome of acute myocarditis [21], [22]. Although myocardial inflammation is an essential etiology for the progression of the disease, most results do not support routine treatment of myocarditis with immunosuppressive drugs [23]. However, studies show some rationale for applying the same immunosuppression protocol to selected patients [24]. Giant cell myocarditis is a rare but
Acknowledgments
We would like to thank Ms. Noriko Tamura and Ms. Yasuko Matsuda for excellent technical assistance.
This study was supported by grants from the Takeda Science Foundation, Mochida Memorial Foundation for Medical and Pharmaceutical Research, and a Grant-in-aid for Science Research from the Japan Society for the Promotion of Science.
References (41)
- et al.
High incidence of myocarditis by endomyocardial biopsy in patients with idiopathic congestive cardiomyopathy
J. Am. Coll. Cardiol.
(1984) - et al.
Tumor necrosis factor receptor -1 and -2 double deficiency reduces graft arterial disease in murine cardiac allografts
Am. J. Transplant.
(2003) - et al.
Combined immunosuppression for the treatment of idiopathic giant cell myocarditis
Mayo Clin. Proc.
(1999) - et al.
Giant cell myocarditis responding to immunosuppressive therapy
Chest
(2000) - et al.
Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction
Biochem. Biophys. Res. Commun.
(2000) - et al.
Kerry O’Banion M. Cyclooxygenase-2 modulates brain inflammation-related gene expression in central nervous system radiation injury
Brain Res. Mol. Brain Res.
(2002) - et al.
A novel cyclo-oxygenase-2 inhibitor modulates catabolic and antiinflammatory mediators in osteoarthritis
Biochem. Pharmacol.
(2004) - et al.
COX-2 inhibition enhances the TH2 immune response to epicutaneous sensitization
J. Allergy Clin. Immunol.
(2005) Etiology, evaluation, and management of acute myocarditis
Cardiol. Rev.
(2001)Myocarditis JMCC, pericarditis and other pericardial diseases
Heart
(2000)